Bio-Path Holdings Faces Delisting Concerns

TL;DR

BPTH might get delisted - stock could be toast.

AI Summary

Bio-Path Holdings, Inc. filed an 8-K on September 13, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company's principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas.

Why It Matters

This filing indicates potential issues with Bio-Path Holdings' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a severe risk to investors.

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant
• September 12, 2024 (date) — Earliest event reported
• September 13, 2024 (date) — Filing date
• 4710 Bellaire Boulevard , Suite 210 , Bellaire , Texas 77401 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
• $2,500,000 — holders' equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq C

Filing Documents

• bpth-20240912x8k.htm (8-K) — 36KB
• 0001558370-24-012780.txt ( ) — 153KB
• bpth-20240912.xsd (EX-101.SCH) — 3KB
• bpth-20240912_lab.xml (EX-101.LAB) — 16KB
• bpth-20240912_pre.xml (EX-101.PRE) — 10KB
• bpth-20240912x8k_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on March 12, 2024, Bio-Path Holdings, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum stockholders' equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). On April 26, 2024, in accordance with Nasdaq Listing Rule 5810(c)(2)(A), the Company submitted a plan to Nasdaq to regain compliance (the "Compliance Plan") with the Stockholders' Equity Requirement and on June 12, 2024, the Company received a letter from Nasdaq granting an extension (the "Extension Letter") until September 8, 2024 to demonstrate compliance with the Stockholders' Equity Requirement. On September 12, 2024, the Company received a delisting determination letter from Nasdaq advising the Company that the Company did not meet the terms of the Extension Letter. Specifically, the Company did not confirm or demonstrate compliance with the Stockholders' Equity Requirement by completing its proposed transactions as set forth in the Extension Letter. As a result, unless the Company requests an appeal of the Staff's determination, trading of the Company's common stock will be suspended at the opening of business on September 23, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC") which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company intends to submit a hearing request to the Nasdaq Hearings Panel (the "Panel") no later than 4:00 p.m. Eastern Time on September 19, 2024, which request will stay suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision. At th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: September 13, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR